FDA to introduce Wholesale Distributor Verification Requirements
Recommendation

8 September 2026
Basel, Switzerland
Specifics in the Distribution of Medicinal Products
The US Food and Drug Administration FDA has published a Compliance Policy Guidance for Industry "Wholesale Distributor Verification Requirement for Saleable Returned Drug Product".
This Guidance is part of FDA's Drug Supply Chain Security Act (DSCSA) and will require wholesale distributors to verify a product identifier prior to further distributing returned product. To address concerns expressed by stakeholders and to minimize possible disruptions in the pharmaceutical distribution supply chain, FDA does not intend to take action against wholesale distributors who do not, prior to November 27, 2020, verify a product identifier prior to further distributing returned product as required under the DSCSA. This represents a 1-year delay in enforcement of this DSCSA requirement.
Related GMP News
12.05.2026European GDP Association Developments January through April 2026
12.05.2026How Are Service Providers Qualified in a GDP Environment?
12.05.2026Questions and Answers from the ECA Webinar "GDP Update 2026" - Part 3
11.05.2026European GDP Association Developments January through April 2026
21.04.2026Implementation of GDP for Pharmaceutical Products in Hong Kong
21.04.2026China's NMPA: Guiding Opinions & Q&A on Standardising Modern Pharmaceutical Logistics


